Although Illumina's failure to acquire Pacific Biosciences stood out in 2019, the upward trend in M&A activity in the omics space in 2018 continued last year.
Researchers found that about 12 percent to 15 percent of breast cancer patients carry multiple mutations in the gene, 95 percent of which are double mutations.
The company released data showing that its panel detects early-stage liver cancer with 71 percent sensitivity compared to 25 percent for the standard test.
AlloSure 3.0 can diagnose the very early stages of T-cell mediated rejection, allowing clinicians to begin anti-rejection therapies and monitor treatment.
Following its departure from the European Union, the UK is to implement a fast-track visa program aimed at attracting scientific talent to Britain, according to BBC News.
ScienceInsider reports that researchers in Brazil are concerned that a creationist was chosen to run the agency that oversees graduate study programs there.
In PLOS this week: common variant associated with BMI in Arctic populations, analysis of microRNA markers associated with being born small for gestational age, and more.
